Piramal Pharma is an API and finished-dose manufacturer based in India. It holds 62 active US drug master files and 29 valid CEPs. Its filings concentrate with EMA, AIFA (IT) and US FDA. Its GMP standing is certified by MHRA (UK), EMA and US FDA, among 10 authorities. Its most recent recorded inspection, by US FDA, closed on 10 December 2025 as VAI. Customs aggregates show $385.3M of exports covering 2,966 molecules to 100 destinations in 2025.
NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.
| Site | FDA FEI |
|---|---|
| Bethlehem, United Arab Emirates | Not on file |
| Morpeth, United Arab Emirates | Not on file |
| Canada, Canada | 3002808377 |
| Rüschlikon, Switzerland | Not on file |
| WEST DRAYTON, United Kingdom | Not on file |
| Morpeth, United Kingdom | Not on file |
20 further sites are on record.
| Molecule | Regulators | Docs |
|---|---|---|
| Verapamil | EDQM, SFDA (Saudi Arabia), US FDA | 4 |
| Baclofen | EDQM, SFDA (Saudi Arabia), US FDA | 3 |
| Diltiazem | EDQM, US FDA | 3 |
| Amiodarone | EDQM, US FDA | 2 |
| Aprepitant | EDQM, US FDA | 2 |
| Bisoprolol | EDQM, US FDA | 2 |
| Brimonidine | EDQM, US FDA | 2 |
| Cinacalcet | SFDA (Saudi Arabia), US FDA | 2 |
| Desmopressin | EDQM, US FDA | 2 |
| Entacapone | EDQM, US FDA | 2 |
| Isoflurane | SFDA (Saudi Arabia), US FDA | 2 |
| Ketoconazole | EDQM, US FDA | 2 |
| Leuprolide | EDQM, US FDA | 2 |
| Mebeverine | EDQM, SFDA (Saudi Arabia) | 2 |
| Mirabegron | EDQM, US FDA | 2 |
| Misoprostol | EDQM, US FDA | 2 |
| Oxytocin | EDQM, US FDA | 2 |
| Terlipressin | EDQM, SFDA (Saudi Arabia) | 2 |
| Trazodone | EDQM, US FDA | 2 |
| Abacavir | SFDA (Saudi Arabia) | 1 |
| Acyclovir | US FDA | 1 |
| Anagrelide | US FDA | 1 |
| Armodafinil | US FDA | 1 |
| Azilsartan Medoxomil | US FDA | 1 |
| Bexagliflozin | US FDA | 1 |
| Buserelin | EDQM | 1 |
| Calcitonin (Salmon) | EDQM | 1 |
| Cetrorelix | US FDA | 1 |
| Clobazam | US FDA | 1 |
| Cloprostenol | US FDA | 1 |
| Dabigatran Etexilate | US FDA | 1 |
| Dabigatran Etexilate Mesilate | EDQM | 1 |
| Dapagliflozin | US FDA | 1 |
| Dapagliflozin Propanediol | SFDA (Saudi Arabia) | 1 |
| Deferasirox | US FDA | 1 |
| Desflurane | US FDA | 1 |
| Dexlansoprazole | US FDA | 1 |
| Donepezil | US FDA | 1 |
| Dronedarone | US FDA | 1 |
| Droxidopa | US FDA | 1 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| EMA | 70 | 8 |
| AIFA (IT) | 39 | None |
| US FDA | 37 | 6 |
| FAMHP (BE) | 22 | None |
| MPA (SE) | 19 | None |
| DIGEMAPS (DO) | 19 | None |
| MHRA (UK) | None | 20 |
| ZLG (DE) | None | 6 |
| MFDS (Korea) | None | 2 |
| NAFDAC (NG) | None | 2 |
| ANVISA (Brazil) | None | 2 |
| NSW_HEALTH | None | 2 |
| NCELS (KZ) | None | 1 |
| TMDA (TZ) | None | 1 |
| Year | Revenue | Exports | Destinations |
|---|---|---|---|
| 2026 YTD | $1.0B | $395.6M | 52 |
| 2025 | $1.1B | $385.3M | 100 |
| 2024 | $976.5M | $373.2M | 91 |
| 2023 | Not reported | $215.7M | 100 |
Export figures are customs aggregates. We do not publish the identity of any buyer. Revenue shown in US dollars, converted from the reported currency.
Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.
Choose your molecules and target markets. Piramal Pharma comes back tiered against every other supplier able to file there.
Start for freeRanked by shared active ingredients where we have them, otherwise by country and comparable credentials.